Back to homepage

Haematology and Oncology

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Authors: Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.


Therapeutics for paediatric oncological emergencies

Authors: Karen Ka Yan Leung, Kam Lun Hon, Wun Fung Hui, Alexander KC Leung, Chi Kong Li

Keywords: acute respiratory distress syndrome (ARDS), Cancer, critical care, disseminated intravascular coagulation, hyperleukocytosis, oncologic emergency, paediatrics, posterior reversible encephalopathy syndrome (PRES), sepsis, superior mediastinal syndrome, therapeutics, treatment, tumour lysis syndrome. Citation: Leung KKY, Hon KL, Hui WF, Leung AKC, Li


Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer

Authors: Iris Y Sheng, Pedro Barata, Raafat Alameddine, Jorge A Garcia

The aim of this narrative review is to discuss the importance of defining advanced disease by volume, the necessity for treatment intensification, and the current and future landscape of metastatic hormonesensitive prostate cancer management.


Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Authors: Xenophon Kassianides BSc (Hons), MBBS, MRCP(UK), Sunil Bhandari MBChB, MRCP, FRCP, PhD, M Clin Edu, FHEA

This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.


Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Authors: Diego Conde-Royo MD, Luis Miguel Juárez-Salcedo MD, Samir Dalia MD

This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.